Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide

#1300

Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.

Aim(s): The purpose is to show the value of Somatostatin Receptor Scintigraphy (SRS) with hybrid imaging in the management of NET.

Materials and methods: 49 patients (25 males and 24 female) aged 50.6±14.3 years (16 to 78 years, median age 54 years) underwent 52 SRS. Indications were as follows, search for a primitive and staging in 23 cases (44.2%), preoperative with known primitive in 16 cases (30.8%) and post operative in 13 cases (25%).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Khamla E

Authors: Ben Sellem D, Khamla E, Ben Slimene M,

Keywords: Neuroendocrine tumor,